Last updated on June 2019

Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)


Brief description of study

In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy. The primary study hypothesis is that treatment with pembrolizumab will result in a clinically meaningful response.

Clinical Study Identifier: NCT02625961

Find a site near you

Start Over

Merck Sharp & Dohme

North Ryde, Australia
  Connect »

MSD Brasil

Sao Paulo, Brazil
  Connect »

Merck Canada

Kirkland, QC Canada
  Connect »

MSD K.K.

Chiyoda-Ku, Tokyo, Japan
  Connect »

MSD Korea LTD

Seoul, Korea, Republic of
  Connect »

MSD Sweden

Stockholm, Sweden
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.